pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$KPTIKaryopharm Therapeutics Inc.

$KPTI
Newton, MA, USupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Marketed: 1Unknown: 1
1Marketed1Unknown
Marketed
selinexor
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Exportin-1
drug
XPOVIO
1 INDICATIONS AND USAGE XPOVIO is a nuclear export inhibi…
Exportin-1

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3Study of Selinexor in Combination With Ruxolitinib in Myelofibrosisactive not recruitingn=353
  • phase2A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.recruitingn=127
  • phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphomaactive not recruitingn=501
  • phase3Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinomarecruitingn=276
  • phase3Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]completedn=263
  • —Karyopharm Expanded Access Program for Selinexoravailable
  • phase2A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopeniarecruitingn=58
  • phase2Selinexor and Backbone Treatments of Multiple Myeloma Patientsrecruitingn=300
🐶 Hiring Signal
No open roles indexed yet — view Karyopharm Therapeutics Inc. jobs →

News

  • Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft
    Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with A…
    biospace · 14d ago
  • Karyopharm, deep in debt, to sell itself in bankruptcy
    The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.
    biopharma_dive · 14d ago
  • Karyopharm plans to merge with Ayrmid, the company that tried buying bluebird
    With few options remaining, a commercial-stage blood cancer biotech will go through a bankruptcy process and plans to merge with another drugmaker in the blood disorder field. Karyopharm Therapeuti…
    endpoints · 14d ago
  • Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned merger
    In an answer to Karyopharm's cash crisis, Irish biotech Ayrmid has agreed to make the first bid on the struggling biopharma's assets in a court supervised auction, teeing up a potential hematology…
    fiercebiotech · 15d ago
  • Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
    Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…
    biopharma_dive · 2mo ago
  • Karyopharm has a month left to salvage its cancer expansion plans
    A commercial-stage cancer drugmaker with a market cap about one-third the size of its projected 2026 revenues is on the brink of defaulting. Karyopharm Therapeutics said Thursday that it has until ...
    endpoints · 3mo ago
identifiers
ticker
$KPTI
SEC CIK
0001503802
country
US
source
sec_tickers
top tags
DLBCL1Oncology1
mentioned in
6news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?